Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Tolerability of Recombinant Human Clara Cell 10kDa Protein (rhCC10) Delivered Intratracheally to Premature Neonates With Respiratory Distress Syndrome

Trial Profile

Safety and Tolerability of Recombinant Human Clara Cell 10kDa Protein (rhCC10) Delivered Intratracheally to Premature Neonates With Respiratory Distress Syndrome

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 09 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Uteroglobin (Primary)
  • Indications Bronchopulmonary dysplasia; Respiratory distress syndrome
  • Focus Adverse reactions
  • Sponsors Clarassance
  • Most Recent Events

    • 08 Dec 2015 Retrospective analysis of long-term follow-up data from the phase 1b part of this trial were presented at the Hot Topics in Neonatology Annual Meeting, according to a Therabron Therapeutics media release.
    • 08 Dec 2015 Results published in a Therabron Therapeutics media release.
    • 24 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top